With lumasiran on the FDA's doorstep, Alnylam reads out new PhIII data in PH1

Nicole DeFeudis

Editor

Just over a month away from its December PDUFA date, Alnylam flaunted new data from two Phase III studies to back lumasiran in primary hyperoxaluria …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

With lumasiran on the FDA's doorstep, Alnylam reads out new PhIII data in PH1

Nicole DeFeudis

Editor

Sign up to read this article for free.

Novo Nordisk partners with Broad Institute spinout Photys after the startup's layoffs

Exclusive: Insitro makes headway on the harder road, discovering new ALS drug target

SiteOne Therapeutics, a pain biotech that's partnered with Vertex, nabs $100M

Aurion’s eye cell therapy improves vision in small study, plots Phase 3 trial

In surprise move, FDA's No. 2 Bumpus to leave agency at end of 2024

Pfizer’s message to investors: The ship is steadying in 2025 (even if Washington is turbulent)

With lumasir­an on the FDA's doorstep, Al­ny­lam reads out new PhI­II da­ta in PH1

Nicole DeFeudis

Editor

Sign up to read this article for free.

more like this

No­vo Nordisk part­ners with Broad In­sti­tute spin­out Pho­tys af­ter the star­tup's lay­offs

Ex­clu­sive: In­sitro makes head­way on the hard­er road, dis­cov­er­ing new ALS drug tar­get

SiteOne Ther­a­peu­tics, a pain biotech that's part­nered with Ver­tex, nabs $100M

Au­ri­on’s eye cell ther­a­py im­proves vi­sion in small study, plots Phase 3 tri­al

In sur­prise move, FDA's No. 2 Bum­pus to leave agency at end of 2024

Pfiz­er’s mes­sage to in­vestors: The ship is steady­ing in 2025 (even if Wash­ing­ton is tur­bu­lent)

With lumasiran on the FDA's doorstep, Alnylam reads out new PhIII data in PH1

Novo Nordisk partners with Broad Institute spinout Photys after the startup's layoffs

Exclusive: Insitro makes headway on the harder road, discovering new ALS drug target

SiteOne Therapeutics, a pain biotech that's partnered with Vertex, nabs $100M

Aurion’s eye cell therapy improves vision in small study, plots Phase 3 trial

In surprise move, FDA's No. 2 Bumpus to leave agency at end of 2024

Pfizer’s message to investors: The ship is steadying in 2025 (even if Washington is turbulent)